Stock Analysis on Net
Stock Analysis on Net

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Common-Size Income Statement

Regeneron Pharmaceuticals Inc., common-size consolidated income statement

Microsoft Excel
12 months ended: Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Net product sales 53.96 56.63 75.39 65.52 61.48
Collaboration revenue 41.95 40.37 22.86 27.92 33.26
Other revenue 4.09 3.00 1.75 6.56 5.26
Revenues 100.00% 100.00% 100.00% 100.00% 100.00%
Cost of goods sold -7.11 -6.57 -11.03 -5.79 -4.61
Cost of collaboration and contract manufacturing -6.74 -6.25 -4.13 -7.39 -5.34
Cost of revenues -13.84% -12.82% -15.17% -13.18% -9.95%
Gross profit 86.16% 87.18% 84.83% 86.82% 90.05%
Research and development -33.84 -29.51 -17.80 -31.15 -38.62
Acquired in-process research and development -1.42 -2.10 -0.30 -1.04 0.00
Selling, general, and administrative -20.06 -17.38 -11.35 -15.84 -23.33
Other operating income (expense), net 0.02 0.74 0.28 3.30 0.00
Income from operations 30.85% 38.93% 55.67% 42.09% 28.10%
Other income (expense), net 1.72 1.47 2.71 3.42 3.17
Interest expense -0.56 -0.49 -0.36 -0.67 -0.38
Other income (expense) 1.16% 0.98% 2.36% 2.75% 2.79%
Income before income taxes 32.01% 39.91% 58.03% 44.84% 30.89%
Income tax expense -1.87 -4.28 -7.78 -3.50 -3.98
Net income 30.14% 35.64% 50.25% 41.35% 26.91%

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Income statement item Description The company
Income from operations The net result for the period of deducting operating expenses from operating revenues. Regeneron Pharmaceuticals Inc. income from operations as a percentage of revenues decreased from 2021 to 2022 and from 2022 to 2023.
Income before income taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Regeneron Pharmaceuticals Inc. income before income taxes as a percentage of revenues decreased from 2021 to 2022 and from 2022 to 2023.
Net income The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Regeneron Pharmaceuticals Inc. net income as a percentage of revenues decreased from 2021 to 2022 and from 2022 to 2023.